期刊
BLOOD
卷 118, 期 7, 页码 1801-1805出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-340620
关键词
-
类别
资金
- Maryland Stem Cell Research Fund [106408, 108563]
- National Institutes of Health [102681]
- NYSTEM [C024406]
- Johns Hopkins Institute for Cell Engineering
EBV-immortalized B lymphocyte cell lines have been widely banked for studying a variety of diseases, including rare genetic disorders. These cell lines represent an important resource for disease modeling with the induced pluripotent stem cell (iPSC) technology. Here we report the generation of iPSCs from EBV-immortalized B-cell lines derived from multiple inherited disease patients via a nonviral method. The reprogramming method for the EBV cell lines involves a distinct protocol compared with that of patient fibroblasts. The B-cell line-derived iPSCs expressed pluripotency markers, retained the inherited mutation and the parental V(D)J rearrangement profile, and differentiated into all 3 germ layer cell types. There was no integration of the reprogramming-related transgenes or the EBV-associated genes in these iPSCs. The ability to reprogram the widely banked patient B-cell lines will offer an unprecedented opportunity to generate human disease models and provide novel drug therapies. (Blood. 2011; 118(7): 1801-1805)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据